Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We investigated the phenotypic characteristics of the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) asthma cohort by applying published MC activation signatures to the sputum cell transcriptome. Methods: Eighty-four participants with SA, 20 with mild/moderate asthma (MMA), and 16 healthy participants without asthma were studied. We calculated enrichment scores (ESs) for nine MC activation signatures by asthma severity, sputum granulocyte status, and three previously defined sputum molecular phenotypes or transcriptome-associated cluster...
BACKGROUND: Sputum analysis in asthmatic patients is used to define airway inflammatory processes an...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...
Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but t...
Rationale: mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but t...
BACKGROUND: Mast cells (MC) play a role in inflammation and both innate and adaptive immunity but th...
Mast cells are a resident inflammatory cell of the airways, involved in both the innate and adaptive...
Mast cells are a resident inflammatory cell of the airways, involved in both the innate and adaptive...
BACKGROUND: Asthma is a chronic inflammatory disease involving diverse cells and mediators whose int...
Background Interleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and...
Background—Patients with severe asthma have increased granulocytes in their sputum compared to patie...
Background Interleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and...
Rationale: Asthma is a heterogeneous disease driven by diverse immunologic and inflammatory mechanis...
Background: Sputum analysis in asthmatic patients is used to define airway inflammatory processes an...
BackgroundInterleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and ...
BACKGROUND: Sputum analysis in asthmatic patients is used to define airway inflammatory processes an...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...
Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but t...
Rationale: mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but t...
BACKGROUND: Mast cells (MC) play a role in inflammation and both innate and adaptive immunity but th...
Mast cells are a resident inflammatory cell of the airways, involved in both the innate and adaptive...
Mast cells are a resident inflammatory cell of the airways, involved in both the innate and adaptive...
BACKGROUND: Asthma is a chronic inflammatory disease involving diverse cells and mediators whose int...
Background Interleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and...
Background—Patients with severe asthma have increased granulocytes in their sputum compared to patie...
Background Interleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and...
Rationale: Asthma is a heterogeneous disease driven by diverse immunologic and inflammatory mechanis...
Background: Sputum analysis in asthmatic patients is used to define airway inflammatory processes an...
BackgroundInterleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and ...
BACKGROUND: Sputum analysis in asthmatic patients is used to define airway inflammatory processes an...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...
BACKGROUND: Transcriptomic changes in patients who respond clinically to biological therapies may id...